Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

Background In most cases, T790M EGFR -positive NSCLC patients receiving osimertinib developed “non-drugable” progression, as the patients with common EGFR -sensitizing mutations were treated with first-line osimertinib. In both settings, chemotherapy represents the standard treatment and local ablat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical & translational oncology 2020-06, Vol.22 (6), p.844-851
Hauptverfasser:	Cortellini, A., Leonetti, A., Catino, A., Pizzutillo, P., Ricciuti, B., De Giglio, A., Chiari, R., Bordi, P., Santini, D., Giusti, R., De Tursi, M., Brocco, D., Zoratto, F., Rastelli, F., Citarella, F., Russano, M., Filetti, M., Marchetti, P., Berardi, R., Torniai, M., Cortinovis, D., Sala, E., Maggioni, C., Follador, A., Macerelli, M., Nigro, O., Tuzi, A., Iacono, D., Migliorino, M. R., Banna, G., Porzio, G., Cannita, K., Ferrara, M. G., Bria, E., Galetta, D., Ficorella, C., Tiseo, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides - therapeutic use Adult Aged Aged, 80 and over Aniline Compounds - therapeutic use Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Combined Modality Therapy Disease Progression ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Female Health Knowledge, Attitudes, Practice Humans Italy Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Lung Neoplasms - surgery Male Medicine Medicine & Public Health Middle Aged Mutation Oncology Research Article Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!